Survival in COPD patients treated with bronchoscopic lung volume reduction.

Autor: Hartman JE; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands. Electronic address: j.hartman@umcg.nl., Welling JBA; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., Klooster K; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., Carpaij OA; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., Augustijn SWS; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands., Slebos DJ; Department of Pulmonary Diseases, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.
Jazyk: angličtina
Zdroj: Respiratory medicine [Respir Med] 2022 May; Vol. 196, pp. 106825. Date of Electronic Publication: 2022 Mar 16.
DOI: 10.1016/j.rmed.2022.106825
Abstrakt: Background and Objective: Severe COPD patients can significantly benefit from bronchoscopic lung volume reduction (BLVR) treatments with coils or endobronchial valves. However, the potential impact of BLVR on survival is less understood. Therefore, our aim was to investigate the survival rate in patients who are evaluated for BLVR treatment and whether there is a difference in survival rate between patients who undergo BLVR treatment and patients who do not.
Methods: We included patients with COPD who visited our hospital for a consultation evaluating their eligibility for BLVR treatment and who performed pulmonary function tests during this visit. Furthermore, vital status was verified.
Results: In total 1471 patients were included (63% female, mean age 61 years). A total of 531 patients (35%) died during follow-up and the median survival time of the total population was 2694 days (95% confidence interval(CI) 2462-2926) which is approximately 7.4 years. The median survival time of patients who were treated with BLVR was significantly longer compared to patients who were not treated with BLVR (3133 days versus 2503 days, p < 0.001), and BLVR was found to be an independent predictor of survival when adjusting for other survival-influencing factors such as age, gender or severity of disease.
Conclusions: Our results suggest that bronchoscopically reducing lung volume in patients with severe hyperinflation may lead to a survival benefit for a population with a severely reduced life expectancy.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: